The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
α7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation
Open accessAbstract
The Alzheimer's disease pathogenic peptide, beta-amyloid42 (A beta 42), induces tau protein phosphorylation. Because hyperphosphorylated tau is a consistent component of neurofibrillary tangles, a pathological hallmark of Alzheimer's disease, we investigated the signaling molecules involved in A beta 42-induced tau phosphorylation. We show that A beta 42 elicited rapid and reversible tau protein phosphorylation on three proline-directed sites (Ser-202, Thr-181, and Thr-231) in systems enriched in alpha 7 nicotinic acetylcholine receptors (alpha 7nAChR) including serum-deprived human SK-N-MC neuroblastoma cells and hippocampal synaptosomes. Although alpha 7nAChR agonists induced similar phosphorylation, pretreatment with antisense-alpha 7nAChR oligonucleotides (in cells) or alpha 7nAChR antagonists (in cells and synaptosomes) attenuated A beta-induced tau phosphorylation. Western analyses showed that the mitogen-activated kinase cascade proteins, ERKs and c-Jun N-terminal kinase (JNK-1), were concomitantly activated by A beta 42, and their respective kinase inhibitors suppressed A beta-induced tau phosphorylation. More importantly, recombinant-activated ERKs and JNK-1 could differentially phosphorylate tau protein in vitro. Thus, the alpha 7nAChR may mediate A beta-induced tau protein phosphorylation via ERKs and JNK-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
The MAPK cascade is required for mammalian associative learning
Atkins, C. M., Selcher, J. C., Petraitis, J. J., Trzaskos, J. M., & Sweatt, J. D. (1998) · Nature Neuroscience · doi:10.1038/2836 · Cited by 1,083
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Dineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462
Zhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110119 · Cited by 418
D'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390
Self-citationWilliamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227
Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226
Research works printed but not linked: 23
- Smith, 1994, Neuropathol. Appl. Neurobiol., 20, 322, 10.1111/j.1365-2990.1994.tb00977.x · DOI
- Lee, 2001, Science, 293, 1446, 10.1126/science.1064684 · DOI
- Rapoport, 2002, Proc. Natl. Acad. Sci. U. S. A., 99, 6364, 10.1073/pnas.092136199 · DOI · Paper page
- Liu, 2001, Proc. Natl. Acad. Sci. U. S. A., 98, 4734, 10.1073/pnas.081553598 · DOI · Paper page
- Wang, 2000, J. Biol. Chem., 275, 5626, 10.1074/jbc.275.8.5626 · DOI · Paper page
- Pettit, 2001, J. Neurosci., 21, 1, 10.1523/JNEUROSCI.21-18-07182.2001 · DOI
- Goedert, 1997, FEBS Lett., 409, 57, 10.1016/S0014-5793(97)00483-3 · DOI · Paper page
- Reynolds, 2000, J Neurochem., 74, 1587, 10.1046/j.1471-4159.2000.0741587.x · DOI · Paper page
- Blum, 1999, J. Neurosci., 19, 3535, 10.1523/JNEUROSCI.19-09-03535.1999 · DOI · Paper page
- Winder, 1999, Neuron, 24, 715, 10.1016/S0896-6273(00)81124-1 · DOI · Paper page
- Fabian-Fine, 2001, J. Neurosci., 21, 7993, 10.1523/JNEUROSCI.21-20-07993.2001 · DOI · Paper page
- Lee, 2003, J. Neurobiol., 25, 25, 10.1002/neu.10203 · DOI
- Wang, 1999, Neuropeptides, 33, 197, 10.1054/npep.1999.0024 · DOI
- Sengupta, 1998, Arch. Biochem. Biophys., 357, 299, 10.1006/abbi.1998.0813 · DOI · Paper page
- Xie, 1998, Brain Res., 798, 173, 10.1016/S0006-8993(98)00407-7 · DOI
- Baumann, 1993, FEBS Lett., 336, 417, 10.1016/0014-5793(93)80849-P · DOI · Paper page
- Litersky, 1996, Biochem. J., 316, 655, 10.1042/bj3160655 · DOI
- Yang, 1993, J. Neurochem., 61, 1742, 10.1111/j.1471-4159.1993.tb09811.x · DOI
- Sontag, 1999, J. Biol. Chem., 274, 25490, 10.1074/jbc.274.36.25490 · DOI · Paper page
- Nagele, 2002, Neuroscience, 110, 199, 10.1016/S0306-4522(01)00460-2 · DOI · Paper page
- Wang, 2000, J. Neurochem., 75, 1155, 10.1046/j.1471-4159.2000.0751155.x · DOI · Paper page
- Dineley, 2002, J. Biol. Chem., 277, 25056, 10.1074/jbc.M200066200 · DOI · Paper page
- Auld, 1998, Trends Neurosci., 21, 43, 10.1016/S0166-2236(97)01144-2 · DOI · Paper page
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Nicotinic acetylcholine receptors and the regulation of neuronal signalling
Dajas-Bailador, F., & Wonnacott, S. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.006 · Cited by 603
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
NMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
The role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
Johansson, N., Eriksson, P., & Viberg, H. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp029 · Cited by 286
Verdier, Y., Zarándi, M., & Penke, B. (2004) · Journal of Peptide Science · doi:10.1002/psc.573 · Cited by 262
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211
Neuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease
Parri, H. R., Hernandez, C. M., & Dineley, K. T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.039 · Cited by 187
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Activating Transcription Factor 3 and the Nervous System
Hunt, D., Raivich, G., & Anderson, P. N. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00007 · Cited by 162
Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans
Kraemer, B. C., Burgess, J. K., Chen, J. H., Thomas, J. H., & Schellenberg, G. D. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl067 · Cited by 150
Campbell, N. R., Fernandes, C. C., Halff, A. W., & Berg, D. K. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0931-10.2010 · Cited by 140
“…2001; Pettit et al., 2001; Dougherty et al., 2003; Grassi et al., 2003; Lee and Wang, 2003; Pym et al., 2005), although it has also been reported to have 7- nAChR agonist activity at low concentrations (Dineley et al., 2001, 2002; Dougherty et al., 2003; Grassi et al., 2003; Wang et al., 2003).”
BackgroundPET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“…tau hyper-phosphorylation, in increasing synaptic strength and stability, and in modulating neuroinflammation by acting on non-neuronal cells (Wang et al., 2003; Conejero-Goldberg et al., 2008; Halff et al., 2014; de Oliveira et al., 2016; Maurer and Williams, 2017; Gamage et al., 2020).”
BackgroundTreatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“The major knowledge and research on the molecular mechanisms of AD pathogenesis led to the study with interest of the α 7 nicotinic acetylcholine receptor ( α 7nAChR) that binds with high-affinity the soluble amyloid β 1-42(A β 42) triggering the protein tau hyperphosphorylation [158,159].”
BackgroundSmall, D. H., Maksel, D., Kerr, M. L., Ng, J., Hou, X., Chu, C., Mehrani, H., Unabia, S., Azari, M. F., Loiacono, R., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04444.x · Cited by 69
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β
Wang, Z.-C., Zhao, J., & Li, S. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1383-2 · Cited by 54
Burns, L. H., Pei, Z., & Wang, H. (2023) · Drug Development Research · doi:10.1002/ddr.22085 · Cited by 35
Self-citationBeta-amyloid oligomers: recent developments
Borutaite, V., Morkuniene, R., & Valincius, G. (2011) · bmc · doi:10.1515/bmc.2011.019 · Cited by 9
Metadata
- Authors
- Wang, H.-Y., Li, W., Benedetti, N. J., & Lee, D. H. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 278
- Issue
- 34
- Pages
- 31547-31553
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1965185022
- Cited by
- 185
- References
- 12
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6269 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.